February 2018 Meeting Announcement, Delaware Valley Mass Spectrometry Discussion Group
- Topic: "Imaging Mass Spectrometry: A New Frontier in Drug Discovery and Development
- Speaker:Jeremy Barry, GSK
- Date: Monday, February 12, 2018. 6:00 PM
- Please RSVP to XQiu2@ITS.JNJ.com by Thursday February 8.
- Time: Social Hour: 6:00 PM.
Talk: 7:00 PM.
- Place: Department of Chemistry, Villanova University (Mendel Hall 154)
Parking for the monthly meetings of the DVMSDG will change on a monthly basis due to heavy construction on campus over the next 1-2 years. Please check monthly for parking updates. The one-way access road to the Mendel Lot (S-3) from the Main Campus Gate on Ithan Avenue is now reopened. Please be aware this is a one-way street from the Connelly Center to the Mendel Lot. The March meeting will be during fall/winter/spring breaks and traffic on campus should be greatly reduced. Evening classes will be going on during the other months and parking in Mendel may be limited.
1. To access the Mendel Lot off of Spring Mill Road, enter through the guard shack on Ithan Avenue and show your parking pass. If the Mendel lot is full, he main parking garage (I-1) is across Lancaster Avenue and the guards may direct you to park there.
2. When leaving, you MUST exit through the Mendel Lot gate. The gate will open automatically.
Since its inception, imaging mass spectrometry (IMS) has demonstrated promise as a label free method for selectively evaluating the tissue distribution of a variety of analyte classes from lipids and small molecule drugs up to peptides and proteins. Over two decades of development in the field of IMS have yielded a robust technique that is capable of much more than just generating "pretty" pictures. This unique combination of spatial information with the inherent qualities of mass spectrometry, such as selectivity and parallel detection, have helped highlight IMS a powerful tool for molecular histology. These capabilities are of particular interest to the pharmaceutical industry as they can be used to provide supporting evidence of drug exposure at the site of action and the corresponding expression of pharmacological activity which are two of the key pillars that define the success of a drug candidate. Within GSK, our group utilizes IMS coupled with high resolving power high mass accuracy FT-ICR MS to address questions relating to drug efficacy and safety. Our goal is to contextualize drug and/or metabolite distribution with changes in endogenous species to enhance understanding of the pharmacological effect and help drive decision making. Additionally, we have contributed to the advancement and validation of the quantitative aspects of IMS as well as adapted new tools such as penetration depth analysis to aid in the evaluation of dermally applied pharmaceuticals.
Jeremy Barry is an Investigator in the Ex Vivo Bioimaging group at GlaxoSmithKline. This group employs imaging mass spectrometry as a label free method to elucidate drug/metabolite distribution and assess pharmacodynamic changes of endogenous compounds in preclinical and clinical samples.
Jeremy holds BS degrees in Chemistry and Forensic Science from the University of New Haven. He received his MS in Chemistry from University of North Carolina at Greensboro under Dr. Brent Dawson developing a pseudo-stationary phase for capillary electrophoresis. He then continued to North Carolina State University where he received his PhD in Chemistry under Dr. David Muddiman. At NC State, he contributed to the development of the matrix-assisted laser desorption electrospray ionization (MALDESI) ion source for direct analysis and imaging mass spectrometry. In 2014 he started with GSK performing small molecule structure elucidation of impurities and degradants before moving to the Bioimaging group in 2016.
Please send any comments, corrections, or suggestions to
This page has been accessed
times since 9/15 /96 .
Last Updated 1/16/2018